Search

everythinglearnresearchcommunity

for

Search:↓

KX826 shows promise as a hair loss treatment with a 10% increase in hair count, but concerns about Kintor's marketing practices and the systemic effects of treatments like GT20029 and RU58841 remain. Users express skepticism and hope, with some preferring traditional treatments like finasteride and minoxidil.

Finasteride's effectiveness and side effects may vary based on male phenotypes, with some users noting differences in response related to body and facial hair characteristics. Some users report success with lower doses, while others experience side effects, suggesting individual variability in response to the treatment.

Serum DHT levels and their variations when using dutasteride for hair loss treatment.

The conversation discusses how Caucasian men are more likely to experience hair loss due to genetic predisposition, with factors like the androgen receptor on the X chromosome playing a significant role. The user also expresses confusion about the evolutionary reasons for hair loss, especially in colder climates where it would seem beneficial to retain hair for warmth.

The conversation discusses the effectiveness of Regenera Activia stem cells versus Cellgenic exosomes for hair loss treatment. The user has been using topical minoxidil 5% and 0.001% estradiol for a year without results.

The conversation discusses the price variation of finasteride in India, with examples from different brands. The user seeks advice on choosing a cost-effective yet effective option.

A 23-year-old user shares their hair regrowth journey, questioning if genetics or other factors are at play. They use Rogaine, finasteride, vitamin B12, biotin, Thera M Plus, and derma stamping, and seek advice on their regimen and hair growth patterns.

Balding scalps have more androgen receptors, leading to increased TGF-beta, which causes blood vessel loss and hair follicle miniaturization. Blocking androgen signaling and TGF-beta may help prevent hair loss.

A 17-year-old is concerned about potential hair loss due to maternal genetics and wonders if treatments like Minoxidil, Finasteride, or RU58841 will be effective. They hope their paternal genetics will help prevent hair loss or make treatments more effective.

CRISPR shows promise for treating hair loss by targeting specific genes. Current treatments include Minoxidil and finasteride, but CRISPR could offer a more precise solution, though it is still expensive and in early stages.

The conversation discusses hair loss, genetics, and treatments like Dutasteride. It highlights the influence of genetics on hair loss, noting that indigenous people are less prone to it.

A Silicon Valley-backed company aims to cure hair loss. Exciting advancements include mRNA therapies, gene editing, hair cloning, AR degraders, anti-androgens, cell-based rejuvenation, and AI-based drug discovery, with hopes for FDA approval of GT20029 within 10 years.

The conversation discusses the potential market release of a hair loss treatment called GT20029 by Anageninc, with users expressing interest and discussing the importance of safety and effectiveness. Some users plan to contact Anageninc to show demand for the product.

The user is seeking alternative hair loss treatments due to side effects from finasteride and minoxidil. They are inquiring about the availability of gt20029 from u-lab.

The conversation discusses the variability in effectiveness and safety of generic finasteride from different manufacturers, with some generics potentially containing impurities. Users shared their experiences with various brands, questioning if different brands affect hair loss treatment outcomes.

The conversation discusses why the difference between donor and balding hair isn't studied more to find a cure for hair loss. Treatments mentioned include Minoxidil, finasteride, and RU58841.

The conversation discusses a personalized hair loss treatment plan based on DNA test results, recommending Minoxidil, Dutasteride, 17-alpha Estradiol, Cetirizine, and PRP sessions. The test identifies a high risk of hair loss due to DHT but a good response to Minoxidil, suggesting a tailored approach to treatment.

Why androgenic alopecia affects the scalp rather than other body parts, potential explanations for this phenomenon, treatments available to combat hair loss, and the implications of male attractiveness in modern society.

The user experienced male pattern baldness starting at 18, tried finasteride with no success, and switched to dutasteride, which halted hair loss. Minoxidil had no effect for them, while their brother, who didn't use AR inhibitors, maintained a juvenile hairline and successfully grew a beard with minoxidil, highlighting the unpredictable nature of genetics in hair loss and treatment response.

Finasteride may affect male offspring's fertility and hormonal balance, with debates on whether to discontinue use before conception. Some users report no issues, while others highlight the high doses used in rat studies.

Exploring hair loss treatments beyond DHT, including Minoxidil, pyruvate, Gt20029 targeting androgen receptors, and vasodilators. Other options like Kx826, adenosine signaling, growth factor topicals, and microneedling are also discussed.

The conversation discusses potential advancements in two hair loss drugs, KX-826 and GT20029, and the interest in whether transitioning from oral finasteride to these drugs would maintain hair growth. One reply expresses skepticism about the compounds' representation.

The conversation is about when GT20029, a hair loss treatment, might be available on the grey market, with users discussing the challenges of compounding it and speculating it might be available after phase 2 results, similar to pyri. Specific treatments mentioned are pyri, RU58841, and GT20029.

The conversation is about the effectiveness of hair loss treatments, specifically finasteride and dutasteride, in different populations. Some users believe that the results of Japanese studies may not be relevant to Caucasian men, especially young ones, and that East Asians may respond better to these treatments. Others argue that clinical studies should be the basis for decision-making, while acknowledging that individual responses to medications can vary.

CRISPR Cas9 could potentially treat baldness by targeting specific genes in hair follicles without affecting other body functions. There is optimism about its future use, despite ethical concerns and the current reliance on treatments like minoxidil and finasteride.

A 28-year-old woman with genetic hair loss has tried various treatments, including oral minoxidil, finasteride, dutasteride, vitamins, ketoconazole shampoo, exosome needling, and hair extensions. She plans to pause treatments for pregnancy and is concerned about potential hair loss during that time.

A user is frustrated about early balding despite older male relatives retaining hair into old age. Another user plans to start finasteride soon to address their hair thinning.

Androgenic alopecia (AGA) might have evolved to reduce prostate cancer risk by increasing UV exposure to the scalp, but this theory is debated. Treatments like minoxidil and finasteride are used for AGA, though the exact causes and evolutionary reasons for hair loss are unclear.

The conversation is about the difficulty in obtaining GT20029, a hair loss treatment, due to patent issues and the need to resort to group buys or Chinese labs for acquisition. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.

The conversation discusses various theories of hair loss, including DHT sensitivity and genetic factors, with the user willing to use themselves for research due to having a hair loss gene but different hair loss patterns compared to their brothers. Specific treatments were not mentioned in the provided text.